Professor of Systems Biology, Columbia University
Head of global research and development at Life Technologies
Director, Life Sciences Institute, University of Michigan
CEO of Zero Locus
Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Head of global research and development at Life Technologies
Managing director, the Foundry Group
Vice President for Corporate Engagement, Rose-Hulman Institute of Technology
|
|
GlaxoSmithKline has written Lexington, MA-based Synta Pharmaceuticals (NASDAQ: SNTA) a check for $80 million. The payment is the first installment under a cancer-drug development agreement that could ultimately be worth $1.1 billion for the Lexington firm.
Sponsored · Whitepaper
Staffing companies need to invest in digital tools to recruit, hire, and onboard the best professionals faster and more efficiently.
DocuSign
Sponsored · Whitepaper
Know Your Risk Factors and How to Address Them
RSM
From Our Editors · Video
David Edwards, professor at Harvard University, on the future of food: video interview
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
